Try our beta test site

HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis

This study has been completed.
Information provided by (Responsible Party):
Lexington International, LLC Identifier:
First received: January 26, 2009
Last updated: June 25, 2012
Last verified: June 2012
The purpose of this study is to test whether the stimulation of vascularization and cellular metabolism on the scalp by use of the HairMax LaserComb will produce improvement in the condition of scalp seborrheic dermatitis.

Condition Intervention
Seborrheic Dermatitis
Device: HairMax LaserComb

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Study of the HairMax LaserComb(r) in the Treatment of Seborrheic Dermatitis of the Scalp.

Resource links provided by NLM:

Further study details as provided by Lexington International, LLC:

Primary Outcome Measures:
  • Proportion of subjects achieving a Global Outcome Score (GOS) of 0, 1 or 2 at week 12 [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • Reduction of the Total Dandruff Sum Score (TDSS) from baseline to week 12 [ Time Frame: 12 weeks ]
  • % of subjects achieving a week 12 PGA grade of '1: slight' or '0: none' [ Time Frame: 12 weeks ]
  • % of subjects achieving at least a 2-grade reduction in PGA from baseline to week 12 [ Time Frame: 12 weeks ]

Estimated Enrollment: 10
Study Start Date: January 2009
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LaserComb
Patients aged 18 years and older with a diagnosis of seborrheic dermatitis of the scalp
Device: HairMax LaserComb
LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.

Detailed Description:

This is an open label pilot study to evaluate the effects of the low-level laser light on seborrheic dermatitis of the scalp. Dandruff assessment scores for scalps with seborrheic dermatitis will be assessed at baseline with monthly evaluations during treatment, until final assessment at end of treatment at week 12.

The trial will involve 10 patients aged 18 years and older with a diagnosis of seborrheic dermatitis. Patients will use the LaserComb device three times per week on non-consecutive days for 12 weeks. No other seborrheic dermatitis products will be used during treatment. The investigator will conduct measurements of dandruff at each study visit, as a measure of efficacy.

The trial consists of 4-5 study visits (screening/baseline, week 4, week 8 and week 12). Dandruff evaluation and adverse event assessments will be performed at each visit.

Safety analysis will be assessed based on the reports of adverse events during the study.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of seborrheic dermatitis of the scalp
  • PGA of 2 (mild) or greater at baseline
  • TDSS score at baseline of 2 or greater, for both scaling and inflammation
  • Must agree to use of non-medicated shampoos during study period; must refrain from use of other medicated scalp products during the trial

Exclusion Criteria:

  • Use of any topical or oral products that would affect assessment of the scalp SD condition, in the opinion of the primary investigator, within the following periods prior to baseline:

    • Medicated shampoos within 2 weeks of baseline
    • Topical scalp medications within 2 weeks of baseline
    • Oral medications affecting the scalp within 4 weeks of baseline
    • Other medications determined by the investigator to potentially affect the assessment of SD = washout to be determined by the investigator, as appropriate to the known medication properties
  • Any current or past medical condition, including active dermatitis or any other dermatological condition, which might interfere with assessment of dandruff
  • Patients using any medications that may increase photosensitivity, and thus pose a risk when undergoing LaserComb therapy
  • Patients with known adverse reactions, allergy or hypersensitivity to laser light components/light sensitivity conditions
  • Patients who have received any investigational drug within 30 days prior to study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00830908

Canada, Ontario
Mediprobe Research Inc
London, Ontario, Canada, N5X 2P1
Sponsors and Collaborators
Lexington International, LLC
Study Director: Aditya Gupta, M.D., Ph.D. Mediprobe Research Inc.
  More Information

Responsible Party: Lexington International, LLC Identifier: NCT00830908     History of Changes
Other Study ID Numbers: LEX0903
Study First Received: January 26, 2009
Last Updated: June 25, 2012

Keywords provided by Lexington International, LLC:
seborrheic dermatitis

Additional relevant MeSH terms:
Dermatitis, Seborrheic
Skin Diseases
Sebaceous Gland Diseases
Skin Diseases, Eczematous
Skin Diseases, Papulosquamous processed this record on March 28, 2017